Ta1
Thymosin Alpha 1
Potential Benefits
- Approved in multiple countries for hepatitis B and C treatment
- Research supports enhancement of T-cell maturation and function
- Studies indicate potential as a vaccine adjuvant to improve immune responses
- May support immune function in immunocompromised individuals
- Clinical data suggests potential benefits in combination with cancer immunotherapy
- Research indicates modulation of toll-like receptors and dendritic cell function
Recommended Starting Dose
1.6 mg subcutaneously (standard clinical dose in approved markets)
Based on published research protocols. Not a prescription.
Dosing Protocol
Standard clinical dosing in approved markets is 1.6 mg subcutaneously twice weekly. For hepatitis, treatment courses typically last 6-12 months. As an immune adjuvant, shorter courses may be used. Some protocols use daily dosing for acute immune challenges.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Immune biomarker changes may be measurable within 2-4 weeks. Clinical benefits for hepatitis and immune support typically develop over weeks to months of consistent use.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Generally well-tolerated in clinical studies
- Injection site reactions (mild pain, redness)
- Rare reports of mild fever
- Fatigue
- Muscle aches during initial use
- Theoretical risk of immune over-activation in autoimmune conditions
More in Immune
LL-37
Cathelicidin LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, consisting of 37 amino acids. It is produced by immune cells, epithelial cells, and other tissues as part of the innate immune defense. Beyond direct antimicrobial activity, research suggests it plays roles in immune modulation, wound healing, and inflammation regulation.
KPV
KPV Tripeptide
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the anti-inflammatory properties of the parent hormone without the pigmentation effects. Research has focused on its potential applications in inflammatory bowel disease and skin inflammation.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.